Dr. Ran Reshef, MD
Claim this profileColumbia University Medical Center
Studies Lymphoma
Studies Leukemia
18 reported clinical trials
29 drugs studied
About Ran Reshef, MD
Education:
- Obtained an MD from Columbia University College of Physicians and Surgeons in 2006.
- Completed a Residency in Internal Medicine at NewYork-Presbyterian Hospital/Columbia University Medical Center in 2009.
- Finished a Fellowship in Hematology and Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center in 2012.
Experience:
- Currently serves as an Assistant Professor of Medicine at Columbia University Irving Medical Center.
- Attending physician at NewYork-Presbyterian Hospital/Columbia University Medical Center.
Area of expertise
1Lymphoma
CD19 positive
HLA-A negative
HLA-A positive
2Leukemia
HLA-A negative
HLA-A positive
HLA positive
Affiliated Hospitals
Clinical Trials Ran Reshef, MD is currently running
Stem Cell Transplantation
for Leukemia
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic malignancies.
Recruiting1 award Phase 2
Tabelecleucel
for Post-Transplant Cancer
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Recruiting2 awards Phase 312 criteria
More about Ran Reshef, MD
Clinical Trial Related2 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Ran Reshef, MD has experience with
- Fludarabine
- Cyclophosphamide
- Tabelecleucel
- Idecabtagene Vicleucel
- Lenalidomide
- PBCAR0191
Breakdown of trials Ran Reshef, MD has run
Lymphoma
Leukemia
Acute Lymphoblastic Leukemia
Multiple Myeloma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ran Reshef, MD specialize in?
Ran Reshef, MD focuses on Lymphoma and Leukemia. In particular, much of their work with Lymphoma has involved CD19 positive patients, or patients who are HLA-A negative.
Is Ran Reshef, MD currently recruiting for clinical trials?
Yes, Ran Reshef, MD is currently recruiting for 9 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Ran Reshef, MD has studied deeply?
Yes, Ran Reshef, MD has studied treatments such as Fludarabine, Cyclophosphamide, Tabelecleucel.
What is the best way to schedule an appointment with Ran Reshef, MD?
Apply for one of the trials that Ran Reshef, MD is conducting.
What is the office address of Ran Reshef, MD?
The office of Ran Reshef, MD is located at: Columbia University Medical Center, New York, New York 10032 United States. This is the address for their practice at the Columbia University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.